Publications by authors named "Han Myint"

Claim this Profile
N
NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.
Thejaswini Giridharan, Sora Suzuki, Anm Nazmul H Khan, Qian Liu, Kristopher Attwood, Han Myint

J Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Hypertension in the Asia-Pacific Region: A Structured Review.
Abdul R A Rahman, Jose Donato A Magno, Jun Cai, Myint Han, Hae-Young Lee

Am J Cardiovasc Drugs· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LAIR-1 agonism as a therapy for acute myeloid leukemia.
Rustin R Lovewell, Junshik Hong, Subhadip Kundu, Carly M Fielder, Qianni Hu, Han Myint

J Clin Invest· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer.
Thazin N Aung, Niki Gavrielatou, Ioannis A Vathiotis, Aileen I Fernandez, Saba Shafi, Han Myint

Cancer Res Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.
Lauren Suarez, Ruipeng Wang, Scott Carmer, Daniel Bednarik, Han Myint

Transfus Med Hemother· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported severity of dry eye and quality of life in diabetes.
Md Kaosar Yazdani-Ibn-Taz, Myint Myint Han, Sven Jonuscheit, Andrew Collier, Jane E Nally

Clin Ophthalmol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Raya Mawad, Pamela S Becker, Paul Hendrie, Bart Scott, Brent L Wood, Han Myint

Br J Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal change disease in graft versus host disease: a podocyte response to the graft?
Janna Huskey, Chris Rivard, Han Myint, Scott Lucia, Maxwell Smith

Clin Nephrol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, Han Myint, Sunita Nasta

Leuk Lymphoma· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Azra Raza, Naomi Galili, Scott E Smith, John Godwin, Ralph V Boccia, Han Myint

Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in hematologic stem cell transplant: an update for oral health care providers.
Joel B Epstein, Judith E Raber-Durlacher, Affi Wilkins, Maria-Gabriella Chavarria, Han Myint

Oral Surg Oral Med Oral Pathol Oral Radiol Endod· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
Robert W Chen, Lynne T Bemis, Carol M Amato, Han Myint, Hung Tran

Blood· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.
Richard K Burt, Alberto Marmont, Yu Oyama, Shimon Slavin, Renate Arnold, Han Myint

Arthritis Rheum· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction.
Robert Chen, Brian L Abbott, Han Myint

Clin Adv Hematol Oncol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Nicolaus Kröger, Jose A Perez-Simon, Han Myint, Hans Klingemann, Avichai Shimoni

Biol Blood Marrow Transplant· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Nicolaus Kröger, Georgia Schilling, Hermann Einsele, Peter Liebisch, Avichai Shimoni, Han Myint

Blood· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies: the good, the bad, and the ugly.
Han Myint

J Hematother Stem Cell Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis